logo
Plus   Neg
Share
Email

Bayer, Bristol-Myers Squibb, Ono Pharma Enter Into Clinical Collaboration

Bayer AG, Bristol-Myers Squibb Co.(BMY) and Ono Pharmaceutical Co., Ltd. announced Thursday that the three companies entered into a clinical collaboration.

As per the agreement, the companies would evaluate the combination of Bayer's kinase inhibitor Stivarga or regorafenib and Bristol-Myers Squibb's / Ono's anti-PD-1 immune checkpoint inhibitor, Opdivo or nivolumab in patients with micro-satellite stable metastatic colorectal cancer.

Earlier, the phase III study has shown limited response and hence combination apporoaches were high. In a Phase 1b, the combination of regorafenib and nivolumab has shown promising preliminary efficacy results.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
Follow RTT